In addition, the therapeutic utility of SHP2 inhibitors in this setting is also unknown and could present a therapeutic opportunity as there are currently about 10 SHP2 inhibitor compounds in clinical development, mainly focusing on KRAS G12C mutated lung cancers and other solid tumors [62]. Here, PTPN11 is linked to lung carcinoma.